Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb, Schizophrenia
Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval
Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.
Bristol Myers Gets US Nod for First New Schizophrenia Drug Type in Decades
Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.
Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.
Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This drug takes the first new approach to schizophrenia treatment in decades,” the Food and Drug Administration said.
15h
Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns
Terence Flynn, an analyst from Morgan Stanley, maintained the Sell rating on Bristol-Myers Squibb (BMY – Research Report). The associated ...
12h
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. BMO Capital analyst notes ...
10h
on MSN
These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...
1d
on MSN
Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use
An FDA Advisory Committee on Thursday voted against broader use of immune checkpoint inhibitors Keytruda and Opdivo developed by Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) in certain ...
2d
on MSN
Bristol-Myers Squibb Company (BMY): Among the Dividend Giants with Lowest Short Interest in 2024
We recently compiled a list of the 8 Dividend Giants with Lowest Short Interest in 2024. In this article, we are going to ...
2d
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback